Self-assembling ferritin nanoplatform enables amyloid-β-targeted immunotherapy and cognitive rescue in APP/PS1 mice

Read full text
Authors: Jiaxin Liu, Chenxing Zhang, Lan Zhao, Rui Liu, Tianxin Cao, Daining Zhang, Zhenjiang Liu, Dong Sun, Yong Zhang, Xianghui Yu, Wei Kong, Hui Wu
Cited by: 1
References: 65

Abstract

Alzheimer's disease (AD) is a progressively neurodegenerative disorder. The accumulation and pathological aggregation of amyloid-β (Aβ) peptides are key events in the occurrence and progression of AD, positioning Aβ-targeted immunotherapy as a precision therapeutic approach. We present a click chemistry-assisted modular nanoparticle vaccine, Fe-Spy-3CAβ, constructed via SpyCatcher-SpyTag-mediated site-specific conjugation of Aβ1-6 epitopes onto engineered ferritin nanocages. This self-assembling nanoparticle vaccine elicited enhanced immunogenicity in APPswe/PSEN1dE9 transgenic mice, generating high-titer antibodies that specifically recognize neurotoxic Aβ42 oligomers. The vaccine promotes robust clearance of Aβ plaques in the cortical and hippocampal regions while rescuing spatial memory deficits. Notably, sex-specific differences are observed in pathological clearance and behavioral improvements, with male mice exhibiting better cognitive performance and reduced neuroinflammation compared to female counterparts, highlighting sex-specific differences in AD progression. Further immunization of rhesus monkeys confirmed the potent immunogenicity and favorable safety of Ferritin-based Aβ vaccine. Critically, serum antibodies from vaccinated monkeys specifically bound Aβ plaques in AD model mouse brain tissues.Our modular nanoassembly platform overcomes key limitations of conventional AD vaccines regarding immune activation efficiency and safety profiles, while offering a versatile approach for developing immunotherapies for neurodegenerative diseases.

Fields of Study & Subjects

Biochemical and Structural Characterization Alzheimer's disease research and treatments Nicotinic Acetylcholine Receptors Study

Publication details

Journal / source
Brain Behavior and Immunity
Publisher
Elsevier BV
Volume
135
Pages
106486–106486
Publication date
12 February 2026
Language
EN